ANI PHARMACEUTICALS, INC Research and Development in Process
ANI PHARMACEUTICALS, INC (ANIP) reported Research and Development in Process of $1.15 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2023-03-09
- ANI PHARMACEUTICALS, INC research and development in process for the quarter ending 2022-12-31 was $0.00.
- ANI PHARMACEUTICALS, INC research and development in process for the quarter ending 2021-12-31 was $0.00.
- ANI PHARMACEUTICALS, INC research and development in process for the quarter ending 2021-09-30 was $0.00.
- ANI PHARMACEUTICALS, INC research and development in process for the quarter ending 2021-06-30 was $0.00.
- ANI PHARMACEUTICALS, INC research and development in process for fiscal 2022 was $1.15M.
- ANI PHARMACEUTICALS, INC research and development in process for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- ANI PHARMACEUTICALS, INC research and development in process for fiscal 2020 was $3.75M, a 61.49% increase from fiscal 2019.
- ANI PHARMACEUTICALS, INC research and development in process for fiscal 2019 was $2.32M, a 74.08% increase from fiscal 2018.
| Period end | Research and Development in Process 3 month | Research and Development in Process 6 month | Research and Development in Process 9 month | Research and Development in Process 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $1.15M 10-K · filed 2023-03-09 | ||
| 2022-09-30 | $1.15M 10-Q · filed 2022-11-09 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $0.00 derived: sum of 3 quarters · filed 2022-11-09 | $0.00 10-K · filed 2022-03-15 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | $0.00 derived: sum of 4 quarters · filed 2023-03-09 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $0.00 10-Q · filed 2021-08-06 | $0.00 derived: sum of 3 quarters · filed 2023-03-09 | $0.00 derived: sum of 4 quarters · filed 2023-03-09 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-07 | $0.00 derived: sum of 2 quarters · filed 2023-03-09 | $0.00 derived: sum of 3 quarters · filed 2023-03-09 | $0.00 derived: sum of 4 quarters · filed 2023-03-09 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $0.00 derived: sum of 2 quarters · filed 2023-03-09 | $0.00 derived: sum of 3 quarters · filed 2023-03-09 | $3.75M 10-K · filed 2023-03-09 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-01 | $0.00 derived: sum of 2 quarters · filed 2021-11-01 | $3.75M 10-Q · filed 2021-11-01 | $3.42M derived: sum of 4 quarters · filed 2022-03-15 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $3.75M 10-Q · filed 2021-08-06 | $3.42M derived: sum of 3 quarters · filed 2022-03-15 | $3.75M derived: sum of 4 quarters · filed 2022-03-15 |
| 2020-03-31 | $3.75M 10-Q · filed 2021-05-07 | $3.42M derived: sum of 2 quarters · filed 2022-03-15 | $3.75M derived: sum of 3 quarters · filed 2022-03-15 | $6.08M derived: sum of 4 quarters · filed 2022-03-15 |
| 2019-12-31 | -$329.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $0.00 derived: sum of 2 quarters · filed 2022-03-15 | $2.32M derived: sum of 3 quarters · filed 2022-03-15 | $2.32M 10-K · filed 2022-03-15 |
| 2019-09-30 | $329.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $2.65M derived: sum of 2 quarters · filed 2020-11-05 | $2.65M 10-Q · filed 2020-11-05 | $2.65M derived: sum of 4 quarters · filed 2021-03-11 |
| 2019-06-30 | $2.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $2.32M 10-Q · filed 2020-08-06 | $2.32M derived: sum of 3 quarters · filed 2021-03-11 | $2.32M derived: sum of 4 quarters · filed 2021-03-11 |
| 2019-03-31 | $0.00 10-Q · filed 2020-05-07 | $0.00 derived: sum of 2 quarters · filed 2021-03-11 | $0.00 derived: sum of 3 quarters · filed 2021-03-11 | |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $0.00 derived: sum of 2 quarters · filed 2021-03-11 | $1.33M 10-K · filed 2021-03-11 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $1.33M 10-Q · filed 2019-11-06 | ||
| 2018-06-30 | $1.33M 10-Q · filed 2019-08-07 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $0.00 derived: sum of 2 quarters · filed 2020-02-27 | $0.00 10-K · filed 2020-02-27 | |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $0.00 10-Q · filed 2018-11-06 | ||
| 2017-06-30 | $0.00 10-Q · filed 2018-08-07 | |||
| 2016-12-31 | $0.00 10-K · filed 2019-02-27 | |||
| 2009-12-31 | $9.00M 8-K · filed 2013-01-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |